| You are here: Home: BCU 1|2004: Denise A Yardley, MD: Select publications
Select publications
Publications discussed by Dr Yardley
Baum M et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003;98(9):1802-10. Abstract
Burris HA et al. A Phase I study of GW572016 in patients with solid tumors. Proc ASCO 2003;Abstract 994.
Citron M et al. Superiority of dose-dense (DD) over conventional scheduling (CS) and equivalence of sequential (SC) versus combination adjuvant chemotherapy (CC) for node-positive breast cancer (CALBG 9741, INT C9741). Breast Cancer Res Treat 2002;Abstract 15.
Citron ML et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21(8):1431-9. Abstract
Goss PE et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349(19):1793-802. Abstract
Hainsworth JD et al. Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: A Minnie Pearl Cancer Research Network Phase II trial. J Clin Oncol 2001;19(15):3500-5. Abstract
Jones SE et al. Three year results of a prospective randomized trial of adjuvant chemotherapy for patients (pts) with stage I-III operable, invasive breast cancer comparing 4 courses of doxorubicin/ cyclophosphamide (AC) to 4 courses of docetaxel/cyclophosphamide (TC). Proc ASCO 2003;Abstract 59.
Martin M et al. TAC Improved DFS and OS over FAC in node positive early breast cancer patients, BCIRG-001: 55 months follow-up. Breast Cancer Res Treat 2003;Abstract 43.
Robert N et al. Phase III comparative study of trastuzumab and paclitaxel with and without carboplatin in patients with HER-2/neu positive advanced breast cancer. Breast Cancer Res Treat 2002;Abstract 35.
Sledge GW et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: An Intergroup trial (E1193). J Clin Oncol 2003;21(4):588-92. Abstract
Spector N et al. Safety, clinical efficacy, and biologic assessments from EGF10004: A randomized Phase IB study of GW572016 for patients with metastatic carcinomas overexpressing EGFR or erbB2. Proc ASCO 2003;Abstract 772.
Trudeau ME. Optimizing adjuvant breast cancer chemotherapy: Rationale for the MA.21 study. Oncology (Huntingt) 2001;15(5 Suppl 7):7-13. Abstract
Yardley DA et al. Final results of the Minnie Pearl Cancer Research Network first-line trial of weekly paclitaxel/carboplatin/trastuzumab in metastatic breast cancer. Breast Cancer Res Treat 2002;Abstract 439.
|
